Biofrontera Reports 17% Revenue Growth, Nears FDA Decision on sBCC Treatment

Event summary

  • Q1 2026 revenue rose 17% YoY to $10.1M, with gross margins expanding to 80% from 62% due to a new earnout structure.
  • FDA accepted the sNDA for Ameluz® PDT for superficial basal cell carcinoma (sBCC) with a PDUFA target date of September 28, 2026.
  • Positive Phase 3 results for Ameluz® PDT in actinic keratoses (AKs) and Phase 2b data in acne vulgaris (AV) show pipeline progress.
  • Operating cash balance maintained at $6.3M, down slightly from $6.4M at year-end 2025 but up from $1.8M in Q1 2025.

The big picture

Biofrontera's Q1 2026 results reflect the benefits of its strategic transaction with Biofrontera AG, driving margin expansion and cash conservation. The company's focus on photodynamic therapy (PDT) aligns with growing demand for non-invasive dermatological treatments, but its ability to convert clinical successes into sustained profitability remains a key test. The upcoming FDA decision on sBCC and continued pipeline advancements will shape its medium-term growth trajectory.

What we're watching

Regulatory Catalysts
The September 28, 2026 PDUFA date for sBCC approval will determine the near-term commercial expansion of Ameluz®.
Pipeline Execution
The pace of Phase 1 pharmacokinetics study completion for FDA filing will impact the timeline for additional indications.
Profitability Path
Whether Biofrontera can sustain improved gross margins and reduce operating losses amid higher selling and marketing costs.